title: Letter: Lichenoid eruption induced by etanercept.
abstract: Lichenoid drug eruption is an uncommon, but previously reported, side effect of anti-tumor necrosis factor therapy. The majority of these adverse events relate to infliximab. We report a patient who developed a lichenoid eruption on the back of her hands during etanercept therapy. She improved with topical treatment and discontinuation of the drug was not necessary. The physiopathological link between anti-TNF treatment and lichenoid eruptions remains unclear. It is important to realize that a lichenoid reaction pattern may occur during anti-TNF agent treatment.
authors.forename: Nuria
authors.initials: N
authors.lastname: Barrientos
authors.forename: Sagrario
authors.initials: S
authors.lastname: García-Sánchez
authors.forename: José D
authors.initials: JD
authors.lastname: Domínguez
mesh_terms: D000287:Administration, Topical; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use; D018501:Antirheumatic Agents / Q000009:adverse effects; D001172:Arthritis, Rheumatoid / Q000188:drug therapy; D003875:Drug Eruptions / Q000175:diagnosis* / Q000188:drug therapy; D000068800:Etanercept; D005260:Female; D006801:Humans; D007074:Immunoglobulin G / Q000009:adverse effects*; D017512:Lichenoid Eruptions / Q000139:chemically induced* / Q000188:drug therapy; D008875:Middle Aged; D000068656:Mometasone Furoate; D011244:Pregnadienediols / Q000627:therapeutic use; D018124:Receptors, Tumor Necrosis Factor; D012720:Severity of Illness Index; D016896:Treatment Outcome
chemical_list: D000893:Anti-Inflammatory Agents; D018501:Antirheumatic Agents; D007074:Immunoglobulin G; D011244:Pregnadienediols; D018124:Receptors, Tumor Necrosis Factor; D000068656:Mometasone Furoate; D000068800:Etanercept